Detalhe da pesquisa
1.
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Nature
; 569(7757): 503-508, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-31068700
2.
Addendum: The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature
; 565(7738): E5-E6, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30559381
3.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature
; 483(7391): 603-7, 2012 Mar 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-22460905
4.
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.
Nature
; 468(7326): 968-72, 2010 Dec 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-21107320
5.
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors.
Cell Rep
; 42(4): 112297, 2023 04 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-36961816
6.
Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in NRAS-Mutant Melanoma: Results From the Expansion Arm of a Phase Ib, Open-Label Study.
J Clin Oncol
; 41(14): 2651-2660, 2023 05 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36947734
7.
High-risk neuroblastoma with NF1 loss of function is targetable using SHP2 inhibition.
Cell Rep
; 40(4): 111095, 2022 07 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-35905710
8.
Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Clin Cancer Res
; 27(1): 342-354, 2021 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33046519
9.
LXH254, a Potent and Selective ARAF-Sparing Inhibitor of BRAF and CRAF for the Treatment of MAPK-Driven Tumors.
Clin Cancer Res
; 27(7): 2061-2073, 2021 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33355204
10.
Resistance to allosteric SHP2 inhibition in FGFR-driven cancers through rapid feedback activation of FGFR.
Oncotarget
; 11(3): 265-281, 2020 Jan 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-32076487
11.
Correction: The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 11(14): 1289, 2020 Apr 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32292577
12.
Down-regulation of class II phosphoinositide 3-kinase alpha expression below a critical threshold induces apoptotic cell death.
Mol Cancer Res
; 6(4): 614-23, 2008 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-18403640
13.
SHP2 Inhibition Overcomes RTK-Mediated Pathway Reactivation in KRAS-Mutant Tumors Treated with MEK Inhibitors.
Mol Cancer Ther
; 18(7): 1323-1334, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31068384
14.
Tumor Intrinsic Efficacy by SHP2 and RTK Inhibitors in KRAS-Mutant Cancers.
Mol Cancer Ther
; 18(12): 2368-2380, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31439712
15.
The potent and selective cyclin-dependent kinases 4 and 6 inhibitor ribociclib (LEE011) is a versatile combination partner in preclinical cancer models.
Oncotarget
; 9(81): 35226-35240, 2018 Oct 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-30443290
16.
Allele-Specific Mechanisms of Activation of MEK1 Mutants Determine Their Properties.
Cancer Discov
; 8(5): 648-661, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29483135
17.
Antitumor Properties of RAF709, a Highly Selective and Potent Inhibitor of RAF Kinase Dimers, in Tumors Driven by Mutant RAS or BRAF.
Cancer Res
; 78(6): 1537-1548, 2018 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29343524
18.
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitors.
Nat Med
; 24(4): 512-517, 2018 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-29505033
19.
BRAF-inhibitor Associated MEK Mutations Increase RAF-Dependent and -Independent Enzymatic Activity.
Mol Cancer Res
; 15(10): 1431-1444, 2017 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-28655712
20.
Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.
Clin Cancer Res
; 23(11): 2856-2868, 2017 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27986745